Magnetic resonance spectroscopy in Alzheimer's disease. 2013

Jonathan Graff-Radford, and Kejal Kantarci
Department of Neurology, Mayo Clinic, Rochester, MN, USA.

Aging is the primary risk factor for dementia. With increasing life expectancy and aging populations worldwide, dementia is becoming one of the significant public health problems of the century. The most common pathology underlying dementia in older adults is Alzheimer's disease. Proton magnetic resonance spectroscopy (MRS) may provide a window into the biochemical changes associated with the loss of neuronal integrity and other neurodegenerative pathology that involve the brain before the manifestations of cognitive impairment in patients who are at risk for Alzheimer's disease. This review focuses on proton MRS studies in normal aging, mild cognitive impairment, and dementia, and how proton MRS metabolite levels may be potential biomarkers for early diagnosis of dementia-related pathologic changes in the brain.

UI MeSH Term Description Entries

Related Publications

Jonathan Graff-Radford, and Kejal Kantarci
June 2002, The Lancet. Neurology,
Jonathan Graff-Radford, and Kejal Kantarci
January 2024, Methods in molecular biology (Clifton, N.J.),
Jonathan Graff-Radford, and Kejal Kantarci
January 1993, Neurobiology of aging,
Jonathan Graff-Radford, and Kejal Kantarci
December 2010, Acta neurologica Belgica,
Jonathan Graff-Radford, and Kejal Kantarci
January 2024, Methods in molecular biology (Clifton, N.J.),
Jonathan Graff-Radford, and Kejal Kantarci
January 2011, Journal of Alzheimer's disease : JAD,
Jonathan Graff-Radford, and Kejal Kantarci
May 2014, Current Alzheimer research,
Jonathan Graff-Radford, and Kejal Kantarci
December 2001, Arquivos de neuro-psiquiatria,
Jonathan Graff-Radford, and Kejal Kantarci
January 2000, Acta neurologica Scandinavica. Supplementum,
Jonathan Graff-Radford, and Kejal Kantarci
May 1998, Psychiatry research,
Copied contents to your clipboard!